Feasibility RCT of definitive chemoradiotherapy or chemotherapy and surgery for oesophageal squamous cell cancer

British Journal of Cancer

Volumn 111, Issue 2, 2014, Pages 234-240

  Blazeby, J M ^a,b   Strong, S ^a,b   Donovan, J L ^a   Wilson, C ^a   Hollingworth, W ^a   Crosby, T ^c   Nicklin, J ^b   Falk, S J ^d   Barham, C P ^b   Hollowood, A D ^b   Streets, C G ^b   Titcomb, D ^b   Krysztopik, R ^b,e   Griffin, S M ^f   Brookes, S T ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY HOSPITALS BRISTOL NHS FOUNDATION TRUST   (United Kingdom)

^c Velindre NHS Trust   (United Kingdom)

^d BRISTOL HAEMATOLOGY AND ONCOLOGY CENTRE   (United Kingdom)

^e ROYAL UNITED HOSPITAL   (United Kingdom)

^f ROYAL VICTORIA INFIRMARY   (United Kingdom)

Author keywords

chemoradiotherapy; oesophageal cancer; pilot RCT; qualitative methods; surgery

Indexed keywords

CAPECITABINE; CISPLATIN; FLUOROURACIL;

ADJUVANT CHEMORADIOTHERAPY; ADULT; AGED; ARTICLE; AUDIO RECORDING; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CONTINUOUS INFUSION; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGEAL STENT; FEASIBILITY STUDY; FEMALE; HOSPITAL MANAGEMENT; HUMAN; INDUCTION CHEMOTHERAPY; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; PATIENT PARTICIPATION; PILOT STUDY; PRIORITY JOURNAL; QUALITATIVE RESEARCH; RANDOMIZED CONTROLLED TRIAL (TOPIC); STAFF TRAINING; TUMOR VOLUME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; CISPLATIN; DEOXYCYTIDINE; ESOPHAGEAL NEOPLASMS; FEASIBILITY STUDIES; FEMALE; FLUOROURACIL; HUMANS; MALE; NEOADJUVANT THERAPY; PILOT PROJECTS; TREATMENT OUTCOME;

EID: 84904539961     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.313     Document Type: Article

References (31)

1. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Stewart B, Fleishman SB, de Haes JCJM, Kaasa S, Klee M, Osoba D, Razavi D, Rofe PB, Schraub S, Sneeuw K, Sullivan M, Takeda F; for the European Organization for Research and Treatment of Cancer (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85: 365-376.
2. Allum WH, Stenning S, Bancewicz J, Clark PI, Langley RE (2009) Long term results of a randomized trial of surgery with or without preoperative. J Clin Oncol 27: 5062-5067.
3. Allum AW, Blazeby JM, Griffin SM, Cunningham D, Jankowski JA, Wong R. Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland, the British Society of Gastroenterology and the British Association of Surgical Oncology (2010) Guidelines for the management of oesophageal and gastric cancer. Gut 60: 1449-1472.
4. Bedenne L, Michel P, Bouché O, Milan C, Mariette C, Conroy T, Pezet D, Roullet B, Seitz JF, Herr JP, Paillot B, Arveux P, Bonnetain F, Binquet C (2007) Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 1 25(10): 1160-1168.
5. Blazeby JM, Blencowe NS, Titcomb DR, Metcalfe C, Hollowood AD, Barham CP (2011) Demonstration of the IDEAL recommendations for evaluating and reporting surgical innovation in minimally invasive oesophagectomy. Br J Surg 98: 544-551.
6. Bhangu A, Kolias AG, Pinkney T, Hall NJ, Fitzgerald JE (2013) Surgical research collaboratives in the UK. Lancet 382(9898): 1091-1092.
7. Burmeister BH, Smithers BM, Gebski V, Fitzgerald L, Simes RJ, Devitt P, Ackland S, Gotley DC, Joseph D, Millar J, North J, Walpole ET, Danham JW; Trans-Tasman Radiation Oncology Group; Australasian Gastro-Intestinal Trials Group (2005) Surgery alone versus chemoradiotherapy followed by surgery for respectable cancer of the oesophagus: A randomized controlled phase III trial. Lancet Oncol 6(9): 659-668.
8. Chiu PW, Chan A, Leung SF, Leong HT, Kwong KH, Li MK, Au-Yeung AC, Chung SC, Ng EK (2005) Multicenter prospective randomized trial comparing standard esophagectomy with chemoradiotherapy for treatment of squamous esophageal cancer: early results from the Chinese University Research Group for Esophageal Cancer (CURE). J Gastrointest Surg 9: 794-802.
9. Cook JA (2009) The challenges faced in the design, conduct and analysis of surgical randomised controlled trials. Trials 10: 9.
10. Crosby T, Hurt CN, Falk S, Gollins S, Mukherjee S, Staffurth J, Ray R, Bashir N, Bridgewater JA, Geh JI, Cunningham D, Blazeby J, Roy R, Maughan T, Griffiths G (2013) Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial. Lancet Oncol 14: 627-637.
11. Davies L, Mason JD, Roberts SA, Chan D, Reid TD, Robinson M, Gwynne S, Crosby TD, Lewis WG (2012) Prognostic significance of total disease length in esophageal cancer. Surg Endosc 26(10): 2810-2816.
12. Donovan JL, de Salis I, Toerien M, Paramasivan S, Hamdy FC, Blazeby JM (2014) The intellectual challenges and emotional consequences of equipoise contributed to the fragility of recruitment in six randomized controlled trials. J Clin Epidemiol; e-pub ahead of print 5 May 2014; doi:10.1016/j.jclinepi.2014. 03.010.
13. Donovan J, Mills N, Smith M, Brindle L, Jacoby A, Peters T, Frankel S, Neal D, Hamdy F (2002) Improving design and conduct of randomised controlled trials by embedding them in qualitative research: ProtecT (prostate testing for cancer and treatment) study. BMJ 325: 766-770.
14. Donovan JL, Lane AJ, Peters TJ, Brindle L, Salter E, Gillatt D, Powell P, Bollina P, Neal DE, Hamdy FC. ProtecT Study Group (2009) Development of a complex intervention improved randomization and informed consent in a randomized controlled trial. J Clin Epidemiol 62: 29-36.
15. Donovan JL, Paramasivan S, De Salis i, Toerien M (2014) Clear obstacles and hidden challenges: understanding recruiter perspectives in six pragmatic randomised controlled trials. Trials 15: 5.
16. Glaser BG (1998) Doing Grounded Theory: Issues and Discussions. Sociology Press: Mill Valley, CA, USA.
17. Gwynne S, Hurt C, Evans M, Holden C, Vout L, Crosby T (2011) Definitive chemoradiation for oesophageal cancer-a standard of care in patients with non-metastatic oesophageal cancer. Clin Oncol 23: 182-188.
18. Hirst JSB, Gotley D, Thomas J, Barbour A (2011) Defining cure for esophageal cancer: analysis of actual 5-year survivors following esophagectomy. Ann Surg Oncol 18: 1766-1774.
19. Lagergren P, Fayers P, Conroy T, Stein HJ, Sezer O, Hardwick R, Hammerlid E, Bottomley A, Van Cutsem E, Blazeby JM. European Organisation for Research Treatment of Cancer Gastrointestinal and Quality of Life Groups (2007) Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-OG25, to assess healthrelated quality of life in patients with cancer of the oesophagus, the oesophago-gastric junction and the stomach. Eur J Cancer 43: 2066-2073.
20. Lewin S, Glenton C, Oxman AD (2009) Use of qualitative methods alongside randomised controlled trials of complex healthcare interventions. BMJ 339: b3496.
21. McNair AG, Choh CT, Metcalfe C, Littlejohns D, Barham CP, Hollowood A, Falk SJ, Blazeby JM (2008) Maximising recruitment into randomised controlled trials: the role of multidisciplinary cancer teams. Eur J Cancer 44: 2623-2626.
22. National Oesophago-Gastric Cancer Audit (2012) The Third Annual Report, pp 1-69.
23. NHS Information Centre: London, UK. National Oesophago-Gastric Cancer Audit (2013) The Third Annual Report, pp 1-67.
24. NHS Information Centre: London, UK. Paramasivan S, Huddart R, Hall E, Lewis R, Birtle A, Donovan JL (2011) Key issues in recruitment to randomised controlled trials with very different interventions: a qualitative investigation of recruitment to the SPARE trial (CRUK/07/011). Trials 12: 78.
25. Parameswaran R, McNair A, Avery K, Berrisford RG, Wajed SA, Sprangers MA, Blazeby JM (2008) The role of health-related quality of life outcomes in clinical decision making in surgery for esophageal cancer: a systematic review. Ann Surg Oncol 15(9): 2372-2379.
26. Sobin LH, Wittekind C (2002) Oesophagus (ICD-O C15). In: TNM Classification of Malignant Tumours, Sobin LH, Wittkind C (eds) 6th edn, pp 60-69, Wiley: New York, NY, USA.
27. Stahl M, Stuschke M, Lehmann N, Meyer HJ, Walz MK, Seeber S, Klump B, Budach W, Teichmann R, Schmitt M, Schmitt G, Franke C, Wilke H (2005) Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 23: 2310-2317.
28. Stahl M, Budach W, Meyer HJ, Cervantes A. On behalf of the ESMO Guidelines Working Group (2010) Esophageal cancer: Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(Suppl 5): v46-v49.
29. Teoh A, Chiu P, Yeung W, Liu SY, Wong SK, Ng EK (2013) Long-term survival outcomes after definitive chemoradiation versus surgery in patients with resectable squamous carcinoma of the esophagus: results from a randomized controlled trial. Ann Oncol 24: 165-171.
30. Urba SG, Orringer MB, Turrisi A, Iannettoni M, Forastiere A, Strawderman M (2001) Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 19: 305-313.
31. van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI,Wijnhoven BP, Richel DJ, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, Cuesta MA, Blaisse RJ, Busch OR, ten Kate FJ, Creemers GJ, Punt CJ, Plukker JT, Verheul HM, Spillenaar Bilgen EJ, van Dekken H, van der Sangen MJ, Rozema T, Biermann K, Beukema JC, Piet AH, van Rij CM, Reinders JG, Tilanus HW, van der Gaast A (2012) Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 366: 2074-2084.